Vapotherm® Releases Next Generation of Capital Unit: Precision Flow Hi-VNI™ System

EXETER, N.H.–(BUSINESS WIRE)–Vapotherm, Inc. (NYSE: VAPO), a global medical technology company
focused on the development and commercialization of its proprietary
Hi-VNI® Technology products that are used to treat patients
of all ages suffering from respiratory distress, today announced the
release of the next generation of its capital unit: the Precision Flow
Hi-VNI system. For this generation of the Precision Flow®
system, both the hardware and software have been updated to improve
reliability, and to comply with the EMC 4th Edition
requirements for medical devices, IEC 60601-1-2:2014.

As with all the other models of the Precision Flow system, this
generation provides Hi-VNI Technology, the innovation that delivers
Mask-Free NIV™ for spontaneously breathing patients. “We’re excited to
offer this next generation of the Precision Flow system to our
customers,” said Joe Army, CEO. “We remain dedicated to continuous
improvement in the products and services we offer our customers and
patients and these improvements deliver on that commitment.”

In 2018, the U.S. Food and Drug Administration (FDA) granted the
Precision Flow Hi-VNI system a new product category and product code
(QAV). The FDA also granted an expanded indication for the system that
states it may be used to augment breathing of spontaneously breathing
patients suffering from respiratory distress in a hospital setting. This
patient population is similar to that treated by other forms of
non-invasive ventilation, making the Precision Flow Hi-VNI system a
viable alternative to Non-invasive Positive Pressure Ventilation (NiPPV)
for most patients.

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer
and manufacturer of advanced respiratory technology based in Exeter, New
Hampshire, USA. The company develops innovative, comfortable,
non-invasive technologies for respiratory support of patients with
chronic or acute breathing disorders. Over 1.5 million patients have
been treated with Vapotherm Hi-VNI Technology. For more information,
visit www.vapotherm.com.

Hi-VNI® Technology is mask-free
noninvasive ventilation for spontaneously breathing patients and a
front-line tool for relieving respiratory distress—including
hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe
treatment of undifferentiated respiratory distress with one simple tool.
Hi-VNI Technology’s mask-free interface delivers optimally conditioned
breathing gases, making it comfortable for patients and reducing the
risks and care complexities associated with mask therapies. While being
treated, patients can talk, eat, drink and take medication.

Website Information Vapotherm routinely posts important
information for investors on the Investor Relations section of it’s
website, http://investors.vapotherm.com/.
Vapotherm intends to use this website as a means of disclosing material,
non-public information and for complying with Vapotherm’s disclosure
obligations under Regulation FD. Accordingly, investors should monitor
the Investor Relations section of Vapotherm’s website, in addition to
following Vapotherm’s press releases, Securities and Exchange Commission
filings, public conference calls, presentations and webcasts. The
information contained on, or that may be accessed through, Vapotherm’s
website is not incorporated by reference into, and is not a part of,
this document.

Contacts

Lise Halpern, VP Marketing
603-658-0011, [email protected]

error: Content is protected !!